DAPH
- Product Name
- DAPH
- CAS No.
- 145915-58-8
- Chemical Name
- DAPH
- Synonyms
- DAPH-1 (DAPH;DAPH/CGP 52411;CGP52411, 10 mM in DMSO;DAPH >=98% (HPLC), solid;1H-Isoindole-1,3(2H)-dione, 5,6-bis(phenylamino)-;4,5-Dianilinophthalimide, 5,6-Bis(phenylamino)-1H-isoindole-1,3(2H)-dione, CGP 52411
- CBNumber
- CB2498023
- Molecular Formula
- C20H15N3O2
- Formula Weight
- 329.35
- MOL File
- 145915-58-8.mol
DAPH Property
- Melting point:
- 199-202℃
- Density
- 1.374
- storage temp.
- 2-8°C
- solubility
- DMSO: ~30 mg/mL
- form
- solid
- pka
- 9.06±0.20(Predicted)
- color
- orange
Safety
- Safety Statements
- 36/37
- WGK Germany
- 3
N-Bromosuccinimide Price
- Product number
- D3943
- Product name
- DAPH
- Purity
- ≥98% (HPLC), solid
- Packaging
- 5mg
- Price
- $142.8
- Updated
- 2025/07/31
- Product number
- D3943
- Product name
- DAPH
- Purity
- ≥98% (HPLC), solid
- Packaging
- 25mg
- Price
- $616
- Updated
- 2025/07/31
- Product number
- 29196
- Product name
- DAPH
- Packaging
- 1mg
- Price
- $49
- Updated
- 2024/03/01
- Product number
- 29196
- Product name
- DAPH
- Packaging
- 25mg
- Price
- $651
- Updated
- 2024/03/01
- Product number
- 29196
- Product name
- DAPH
- Packaging
- 5mg
- Price
- $156
- Updated
- 2024/03/01
DAPH Chemical Properties,Usage,Production
Uses
CGP 52411 is a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitmuor activity. It may offer therapeutic agents for the treatment of hyperproliferative diseases.
Definition
ChEBI: 4,5-dianilinophthalimide is phthalimide substituted at the 4- and 5-positions by anilino groups. It has a role as a tyrosine kinase inhibitor and a geroprotector.
Biochem/physiol Actions
DAPH is an inhibitor of Aβ fibril formation; Protein tyrosine kinase inhibitor, specific for EGFR.
in vivo
CGP52411 (3.2 mg/kg, 6.3 mg/kg, 12.5 mg/kg, 25 mg/kg, and 50 mg/kg; oral administration; daily; for 15 days; female BALB/c nude mice) treatment in vivo against xenografts of the A431 and SK-OV-3 tumors, and has antitumor activity[1].
| Animal Model: | Female BALB/c nude mice injected with A431cells[1] |
| Dosage: | 3.2 mg/kg, 6.3 mg/kg, 12.5 mg/kg, 25 mg/kg, and 50 mg/kg |
| Administration: | Oral administration; daily; for 15 days |
| Result: | Antitumor efficacy was obtained at doses between 50 mg/kg and 6.3 mg/kg. |
IC 50
EGFR: 0.3 μM (IC50); Amyloid-β
DAPH Preparation Products And Raw materials
Raw materials
Preparation Products
DAPH Suppliers
- Tel
- --
- Fax
- --
- Country
- Switzerland
- ProdList
- 6896
- Advantage
- 91